Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Revive Therapeutics Ltd (OP:RVVTF)

0.0088 +0.0008 (+10.00%)
Streaming Delayed Price Updated: 3:38 PM EST, Jan 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Revive Therapeutics Ltd

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Revive Therapeutics Submits Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Psyched: Psychedelics In Davos, Prince Harry In The 90s, Cathie Wood's Latest Moves And More ↗
Psychedelics Take Center Stage In Davos Psychedelics will lead the conversation inside the Davos House of Health for a second year in a row this January. 
Via Benzinga
News headline image
Revive Therapeutics To Submit Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Psychedelics Company Revive Raises $3.2M To Target Infectious Diseases, Disorders ↗
Life sciences company Revive Therapeutics Ltd. (OTCQB: RVVTF) raised funds to treat infectious diseases and rare disorders, including meth addiction.< 
Via Benzinga
News headline image
Revive Therapeutics Ltd. Closes $4.3 Million Offering
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Announces Publication Showing Bucillamine’s Potential Impact on COVID-19 Omicron Variants
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Announces Submission of Type C Meeting Request to FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Psyched: First Ayahuasca Pill Created, Psychedelics Legalization Predicted, UK's Research Support And More ↗
Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans The first medical-grade drug candidate of the psychedelic ayahuasca is being developed. 
Via Benzinga
News headline image
Psyence, Revive Therapeutics Ink Private Placements: Capital To Support Drug Trials ↗
Life sciences biotech Psyence Group Inc. (OTCQB: PSYGF) has closed the second tranche of its previously announced private placement of up to $2.2 million (CA$3 million). 
Via Benzinga
News headline image
Revive Therapeutics Ltd. Expands Life Offering to Quebec
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics To Raise Up To $5M Via Private Placement ↗
REVIVE THERAPEUTICS LTD. (OTCQB: RVVTF) (CSE:RVV) announced that it is arranging a private placement of a minimum of $3 million and up to $5 million of units, at a price of $0.15 per unit;. 
Via Benzinga
News headline image
Revive Therapeutics Ltd. Announces Offering of Up to $5 Million
From Revive Therapeutics Ltd.
Via GlobeNewswire
Psychedelic Stock Gainers And Losers From November 30, 2022 ↗
 
Via Benzinga
Revive Therapeutics, Seelos Therapeutics Among Top Psychedelic Movers Of Today ↗
 
Via Benzinga
News headline image
Revive Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today ↗
 
Via Benzinga
Psychedelic Stock Gainers And Losers From November 25, 2022 ↗
 
Via Benzinga
Psychedelic Stock Gainers And Losers From November 24, 2022 ↗
 
Via Benzinga
News headline image
Revive Therapeutics Announces Update for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Psychedelic Stock Gainers And Losers From November 23, 2022 ↗
 
Via Benzinga
Psychedelic Stock Gainers And Losers From November 22, 2022 ↗
 
Via Benzinga
News headline image
Revive Therapeutics Announces FDA Recommendation for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
Psychedelic Stock Gainers And Losers From November 21, 2022 ↗
 
Via Benzinga
Biomind Labs, ATAI Life Sciences Among Top Psychedelic Movers Of Today ↗
 
Via Benzinga
Revive Therapeutics, GH Research Among Top Psychedelic Movers Of Today ↗
 
Via Benzinga
Psychedelic Stock Gainers And Losers From November 16, 2022 ↗
 
Via Benzinga
GH Research, Seelos Therapeutics Among Top Psychedelic Movers Of Today ↗
 
Via Benzinga
News headline image
Compass Pathways, Mind Medicine Among Top Psychedelic Movers Of Today ↗
GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 12.17% at $10.05 
Via Benzinga
News headline image
Seelos Therapeutics, GH Research Among Top Psychedelic Movers Of Today ↗
GAINERS: GH Research (NASDAQ:GHRS) shares closed up 7.91% at $9.96 LOSERS: 
Via Benzinga
News headline image
Psychedelic Stock Gainers And Losers From November 8, 2022 ↗
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 3.85% at $0.14 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.